Advanced search
Start date

Drug discovery and design: antimicrobial peptide B1CTcu5 analogs promising against Mycobacterium tuberculosis

Grant number: 21/14603-5
Support Opportunities:Scholarships abroad - Research Internship - Doctorate
Effective date (Start): September 01, 2022
Effective date (End): August 31, 2023
Field of knowledge:Biological Sciences - Microbiology - Applied Microbiology
Principal Investigator:Fernando Rogério Pavan
Grantee:Cesar Augusto Roque Borda
Supervisor: Paul Robert Hansen
Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
Research place: University of Copenhagen, Denmark  
Associated to the scholarship:20/16573-3 - In vitro and in vivo studies of antimicrobial peptide B1CTcu5 analogs encapsulated in colon-specific microparticles against Mycobacterium tuberculosis, BP.DR


The emergence of multidrug-resistant bacteria that are resistant to most known antibiotics has resulted in a global health crisis. Thus, new antimicrobial drugs with new modes of action are urgently needed. Antimicrobial peptides (AMPs) are part of the innate immune defense of all multicellular organisms. Current development of AMPs as potential antibiotics is an interesting area of research because these molecules generally are not prone to rapid resistance development. Tuberculosis (TB) is a communicable infectious disease caused mainly by the bacillus Mycobacterium tuberculosis. According to the World Health Organization (WHO), this disease is one of the ten main causes of death in the world, but the main one caused by a single infectious agent, rank-ing above HIV/AIDS. The synthetic peptide B1CTcu5 contists of 21 amino acid residues and was originally isolated from the cutaneous secretion from the frog Clinotarsus curtipes. This pep-tide showed a promising effect (including low toxicity) in an initial study against M. tuberculosis. The objective of this research is to obtain new hybrid, conjugated, and/or complexed peptides derived from B1CTcu5 that can improve the initial MIC-values, that can have greater resistance to degradation in biological systems and that have low toxicity. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
POLINARIO, GIULIA; PRIMO, LAURA MARIA DURAN GLERIANI; ROSA, MAIARA ALANE BARALDI CERQUETANI; DETT, FREDDY HUMBERTO MARIN; BARBUGLI, PAULA ABOUD; ROQUE-BORDA, CESAR AUGUSTO; PAVAN, FERNANDO ROGERIO. Antimicrobial peptides as drugs with double response against Mycobacterium tuberculosis coinfections in lung cancer. FRONTIERS IN MICROBIOLOGY, v. 14, p. 17-pg., . (22/09728-6, 20/16573-3, 20/13497-4, 21/14603-5)
DE SOUZA, GUILHERME DA COSTA; ROQUE-BORDA, CESAR AUGUSTO; PAVAN, FERNANDO R.. Beta-lactam resistance and the effectiveness of antimicrobial peptides against KPC-producing bacteria. Drug Development Research, v. 83, n. 7, p. 21-pg., . (21/14603-5, 20/13497-4, 20/16573-3)
ROQUE-BORDA, CESAR AUGUSTO; DA SILVA, PATRICIA BENTO; RODRIGUES, MOSAR CORREA; FILIPPO, LEONARDO DELELLO DI; DUARTE, JONATAS L.; CHORILLI, MARLUS; VICENTE, EDUARDO FESTOZO; GARRIDO, SAULO SANTESSO; PAVAN, FERNANDO ROGENIO. Pharmaceutical nanotechnology: Antimicrobial peptides as potential new drugs against WHO list of critical, high, and medium priority bacteria. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v. 241, p. 18-pg., . (21/14603-5, 20/13497-4, 20/16573-3, 18/25707-3)

Please report errors in scientific publications list using this form.